FASTRACK II

 Kidney — In Follow-up

FASTRACK II
Surgery is the standard treatment for primary kidney cancer. However, in some cases, surgery is either not possible or other health problems make surgery high risk. This study involves a relatively new, highly precise multidirectional radiotherapy technique called Stereotactic Ablative Body Radiotherapy (SABR) which will be applied to all participants.

The aim of the study is to test the ability of the technique to control cancer within the kidney for those people for whom surgery is not an option, and to examine the side effects of the treatment, including how it may affect your kidney’s function.

This study is led by TROG and co-badged by ANZUP Cancer Trials Group and is now closed to recruitment and is in follow up.
If you think this trial might be right for you, please ask your doctor.
Trial Title
TROG 15.03 Focal Ablative STereotactic RAdiosurgery for Cancers of the Kidney – A Phase II Clinical Trial
Cancer Type
Kidney
Trial Status
In Follow-up
Protocol Number
TROG 15.03
Trial Email
FASTRACKII@trog.com.au
Co-ordinating centre
Study Chair
Prof Shankar Siva
Patient Population
Renal cell carcinoma (RCC)
Recruitment Target
70 participants
Detailed Information
ANZCTR
Further Information
ClinicalTrials.gov
Participating Centres
NSW
Calvary Mater Newcastle
Liverpool Hospital - South Western Sydney Local Health District
Royal North Shore Hospital - Northern Sydney Local Health District

VIC
Peter MacCallum Cancer Centre
Alfred Health - The Alfred Hospital

QLD
Princess Alexandra Hospital
Royal Brisbane & Women's Hospital

SA
Royal Adelaide Hospital - Central Adelaide Local Health Network Inc.

Participating Centres